TrialInternational journal of hematology2024

Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial.

Kazuya Shimoda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.